Market claims and efficacy information in direct‐to‐consumer prescription drug print advertisements

Authors

Kathryn J. Aikin PhD, U.S. Food and Drug Administration, Silver SpringFollow
Kevin R. Betts PhD, U.S. Food and Drug Administration, Silver Spring
Aysha Keisler PhD, Ipsos Public Affairs, Washington
Kathryn Schaefer Ziemer PhD, Ipsos Public Affairs, Washington

ORCID IDs

http://orcid.org/0000-0003-0244-6607

Date of this Version

2019

Document Type

Article

Citation

U.S. government works are not subject to copyright.

Comments

Psychol. Mark. 2019;36:747–757. wileyonlinelibrary.com/journal/mar

Abstract

This study examined the impact of “New” and “#1 Prescribed” market claims and quantitative efficacy information on perceptions of a hypothetical prescription drug in a direct‐to‐consumer (DTC) print advertisement. We examined two market claims (New and #1 Prescribed), two efficacy levels (higher and lower), and a control condition without this information. Participants with diabetes were randomized to review one ad version and asked their perceptions of the ad's message, the drug's benefits, side effects and risks, doctors' opinions about the drug, and behavioral intention to use the drug, as well as recall and recognition of drug benefits and risks. Results suggest the market claim affects personal perceptions and perceptions of the ad's message about drug benefits and perceptions about doctors' opinions of the drug. Inclusion of quantitative information about product efficacy did not show a large influence on perceptions. These findings can help inform stakeholders and policy makers as they work to ensure DTC prescription drug promotion does not mislead patients.